Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer (Q39311162)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

1 reference

based on heuristic

inferred from title

Fluorodeoxyglucose Positron Emission Tomography

1 reference

based on heuristic

inferred from title

author name string

Olivier Humbert

1

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Alina Berriolo-Riedinger

2

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Alexandre Cochet

3

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Mélanie Gauthier

4

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Céline Charon-Barra

5

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Séverine Guiu

6

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Isabelle Desmoulins

7

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Michel Toubeau

8

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Inna Dygai-Cochet

9

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Charles Coutant

10

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Pierre Fumoleau

11

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

François Brunotte

12

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

publication date

21 November 2013

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

number of pages

12

1 reference

based on heuristic

inferred from page(s)

European Journal of Nuclear Medicine and Molecular Imaging

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

41

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

416-427

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

Repeated observation of breast tumor subtypes in independent gene expression data sets

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

Breast cancer subtypes and the risk of local and regional relapse.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

St. Gallen 2011: Summary of the Consensus Discussion

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

Variability and reproducibility of hepatic FDG uptake measured as SUV as well as tissue-to-blood background ratio using positron emission tomography in healthy humans.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

Primary systemic chemotherapy of invasive lobular carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

Need for standardization of 18F-FDG PET/CT for treatment response assessments

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

Standards for PET image acquisition and quantitative data analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2616-3

21 January 2018

Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24258007

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes

1 reference

https://pubmed.ncbi.nlm.nih.gov/24258007

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relationship between 18F-FDG uptake and breast density in women with normal breast tissue

1 reference

https://pubmed.ncbi.nlm.nih.gov/24258007

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24258007

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24258007

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/24258007

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/24258007

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24258007

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24258007

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00259-013-2616-3

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39311162&oldid=2246486948"